Novo Nordisk Shares Slide: Doubts Emerge Over CagriSema Trial Results

Novo Nordisk’s stock plummets as CagriSema trial data disappoints investors. The obesity drug’s underwhelming results raise doubts about its potential, impacting the company’s market position. Despite the setback, hope remains for future improvements and Novo Nordisk’s resilience in the competitive healthcare sector.